查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1956792

血友病基因治療市場分析及預測（至2035年）：依類型、產品類型、技術、應用、最終使用者、流程、功能、安裝類型及解決方案分類

Hemophilia Gene Therapy Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Process, Functionality, Installation Type, Solutions
出版日期: | 出版商: Global Insight Services | 英文 302 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

血友病基因治療市場預計將從2024年的5億美元成長到2034年的27.1億美元，複合年成長率約為18.7%。血友病基因治療市場涵蓋了直接針對血友病遺傳病因的創新治療方法，有望提供長期解決方案。這些治療方法旨在恢復缺失凝血因子的生成，從而減少或消除出血發作。隨著研究的深入，由於盛行率的上升、研發投入的增加以及監管部門的核准，該市場蓄勢待發，即將迎來成長。市場關注的重點是提高療效、安全性和可及性，並為個人化醫療以及生物技術公司與醫療服務提供者之間的合作提供了巨大的機會。

受基因工程技術的進步和血友病患者數量的增加的推動，血友病基因治療市場預計將呈現強勁成長。其中，A型血友病基因治療領域成長最為顯著，主要得益於載體技術的重大進步及令人鼓舞的臨床試驗結果。 BB型血友病基因治療緊隨其後，遞送機制的創新提高了治療效果。腺結合病毒（AAV）載體因其已證實的安全性和基因轉移效率而脫穎而出。慢病毒載體由於能夠整合到宿主基因組中並提供長期表達，正迅速成為第二大成長領域。生物技術公司之間的策略聯盟和合作進一步鞏固了市場，推動了創新並加速了研發進程。 CRISPR等新型基因編輯技術的出現為血友病治療提供了盈利的機遇，有望帶來更精準、更持久的治療效果。

市場區隔
類型 A型血友病A，B型血友病
產品 基因治療載體、重組蛋白
科技 腺結合病毒（AAV）載體、慢病毒載體、逆轉錄病毒載體
目的 臨床試驗、研究與開發以及商業用途
最終用戶 醫院、專科診所、研究機構、生物製藥公司
流程 體內基因治療，體外基因治療
功能 基因轉移，基因編輯
安裝類型 獨立式、整合式
解決方案 治療方案、診斷方案

血友病基因治療市場正蓬勃發展，各大區域的市佔率分佈不均。定價策略也不斷調整，以滿足日益成長的創新治療方法需求。在基因工程和個人化醫療技術的推動下，新產品上市速度加快。各公司正致力於建立策略聯盟，以增強產品系列併擴大市場覆蓋範圍。市場格局的特點是擁有豐富的創新治療方法有望徹底改變治療模式。血友病基因治療市場的競爭日益激烈，新參與企業不斷湧現，現有企業之間也出現了整合。監管機構的影響力至關重要，其嚴格的指導方針規範著市場准入和產品核可流程。對競爭對手的比較分析表明，各公司都非常重視臨床療效和安全性。在有利的報銷政策和患者意識不斷提高的推動下，市場蓄勢待發，預計將實現成長。為了增強競爭優勢並掌握新的機遇，各公司紛紛透過策略聯盟和併購來鞏固自身地位。

主要趨勢和促進因素：

受基因研究進展和創新治療方法的推動，血友病基因治療市場正經歷變革性成長。關鍵趨勢包括聚焦個人化醫療，從而實現量身定做的治療方案，改善患者預後並減少副作用。尖端CRISPR技術的整合正在革新基因編輯領域，提供更精準有效的治療選擇。此外，監管機構認知到基因治療在滿足未被滿足的醫療需求方面的潛力，正在加快基因治療的核准流程，為研發投資創造有利環境。血友病患病率的不斷上升以及醫療保健支出的成長，進一步推動了市場擴張。新興市場蘊藏著許多機遇，這些市場的醫療基礎設施正在發展，人們對基因治療的認知也不斷提高。能夠成功應對監管環境並證明其長期療效和安全性的公司有望佔據顯著的市場佔有率。憑藉持續的技術創新和策略合作，血友病基因治療市場預計將保持持續成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • A型血友病A
    • B型血友病
  • 市場規模及預測：依產品分類
    • 基因治療載體
    • 重組蛋白
  • 市場規模及預測：依技術分類
    • 腺結合病毒（AAV）載體
    • 慢病毒載體
    • 逆轉錄病毒載體
  • 市場規模及預測：依應用領域分類
    • 臨床試驗
    • 研究與開發
    • 商業用途
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 專科診所
    • 研究機構
    • 生物製藥公司
  • 市場規模及預測：依製程分類
    • 體內基因治療
    • 體外基因治療
  • 市場規模及預測：依功能分類
    • 基因替代療法
    • 基因編輯
  • 市場規模及預測：依安裝類型分類
    • 獨奏
    • 一體化
  • 市場規模及預測：按解決方案分類
    • 治療方案
    • 診斷解決方案

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • uni Qure
  • Bio Marin Pharmaceutical
  • Sangamo Therapeutics
  • Spark Therapeutics
  • Freeline Therapeutics
  • Hemab Therapeutics
  • Dimension Therapeutics
  • REGENXBIO
  • Intellia Therapeutics
  • Editas Medicine
  • CRISPR Therapeutics
  • Thermo Fisher Scientific
  • Voyager Therapeutics
  • Audentes Therapeutics
  • Bluebird Bio
  • Precision Bio Sciences
  • Poseida Therapeutics
  • Generation Bio
  • Logic Bio Therapeutics
  • Beam Therapeutics

第9章：關於我們

簡介目錄
Product Code: GIS32340

Hemophilia Gene Therapy Market is anticipated to expand from $500.0 million in 2024 to $2.71 billion by 2034, growing at a CAGR of approximately 18.7%. The Hemophilia Gene Therapy Market encompasses innovative treatments that address the genetic root of hemophilia, offering potential long-term solutions. These therapies aim to restore deficient clotting factor production, reducing or eliminating bleeding episodes. As research advances, the market is poised for growth, driven by increasing prevalence, rising R&D investments, and regulatory approvals. The focus is on improving efficacy, safety, and accessibility, with significant opportunities in personalized medicine and partnerships between biotech firms and healthcare providers.

The Hemophilia Gene Therapy Market is poised for robust growth, fueled by advancements in genetic engineering and increasing prevalence of hemophilia. The segment of hemophilia A gene therapies is the top performer, driven by significant advancements in vector technology and promising clinical trial outcomes. Hemophilia B gene therapies follow closely, with innovations in delivery mechanisms enhancing therapeutic efficacy. The adeno-associated virus (AAV) vector sub-segment stands out, benefiting from its proven safety profile and efficiency in gene transfer. Lentiviral vectors are gaining momentum as the second highest performing sub-segment, due to their ability to integrate into the host genome and provide long-term expression. The market is further bolstered by strategic partnerships and collaborations among biotech firms, fostering innovation and accelerating development timelines. The emergence of novel gene-editing technologies, such as CRISPR, presents lucrative opportunities, offering potential for more precise and durable therapeutic outcomes in hemophilia treatment.

Market Segmentation
TypeHemophilia A, Hemophilia B
ProductGene Therapy Vectors, Recombinant Proteins
TechnologyAdeno-Associated Virus (AAV) Vector, Lentivirus Vector, Retrovirus Vector
ApplicationClinical Trials, Research and Development, Commercial Use
End UserHospitals, Specialty Clinics, Research Institutes, Biopharmaceutical Companies
ProcessIn Vivo Gene Therapy, Ex Vivo Gene Therapy
FunctionalityGene Addition, Gene Editing
Installation TypeStandalone, Integrated
SolutionsTherapeutic Solutions, Diagnostic Solutions

The Hemophilia Gene Therapy Market is witnessing a dynamic evolution with varied market share distribution across key regions. Pricing strategies are adapting to accommodate the increasing demand for innovative therapies. New product launches are accelerating, driven by advancements in genetic engineering and personalized medicine. Companies are focusing on strategic collaborations to enhance their product portfolios and expand their reach. The market landscape is characterized by a robust pipeline of novel therapies, promising to revolutionize treatment paradigms. Competition in the Hemophilia Gene Therapy Market is intensifying with the entry of new players and the consolidation of existing ones. Regulatory influences play a pivotal role, with stringent guidelines shaping market entry and product approval processes. Benchmarking against competitors reveals a focus on clinical efficacy and safety profiles. The market is poised for growth, supported by favorable reimbursement policies and increasing patient awareness. Strategic alliances and mergers are prevalent, as companies aim to bolster their competitive edge and capitalize on emerging opportunities.

Geographical Overview:

The Hemophilia Gene Therapy Market is witnessing substantial growth across various regions, each presenting unique opportunities. North America leads the market, driven by advanced healthcare infrastructure and significant investments in gene therapy research. The presence of key industry players and supportive regulatory frameworks further bolster market expansion in this region. Europe follows closely, with a strong focus on innovative healthcare solutions and increasing funding for genetic research. The region's commitment to improving patient outcomes through cutting-edge therapies enhances its market position. In the Asia Pacific, the market is rapidly expanding due to rising healthcare expenditure and growing awareness about gene therapies. Emerging economies, such as China and India, are investing heavily in biotechnology and healthcare advancements. Latin America and the Middle East & Africa represent promising growth pockets. In Latin America, improving healthcare infrastructure and rising demand for advanced treatments are driving market growth. Meanwhile, the Middle East & Africa are increasingly recognizing the potential of gene therapies to address unmet medical needs, fostering market development.

Global tariffs and geopolitical tensions are increasingly influencing the Hemophilia Gene Therapy Market. Japan and South Korea are navigating these complexities by enhancing domestic R&D capabilities and seeking strategic partnerships to mitigate reliance on foreign technologies. China, amid export controls, is accelerating its gene therapy innovation, focusing on self-sufficiency and regulatory advancements. Taiwan, while pivotal in biopharmaceutical production, faces geopolitical vulnerabilities that could disrupt supply chains. The global market shows robust growth, driven by advancements in gene therapy and increasing prevalence of hemophilia. By 2035, the market is anticipated to flourish, contingent on stable geopolitical landscapes and resilient supply chains. Middle East conflicts could indirectly affect this market by influencing energy prices, impacting operational costs and logistical frameworks.

Key Trends and Drivers:

The hemophilia gene therapy market is experiencing transformative growth, driven by advancements in genetic research and innovative treatment methodologies. A key trend is the increasing focus on personalized medicine, allowing for tailored therapies that improve patient outcomes and reduce adverse effects. The integration of cutting-edge CRISPR technology is revolutionizing gene editing, offering more precise and efficient treatment options. Moreover, regulatory bodies are accelerating the approval processes for gene therapies, recognizing their potential to address unmet medical needs. This is fostering a favorable environment for research and development investments. The growing prevalence of hemophilia, coupled with rising healthcare expenditure, is further propelling market expansion. Opportunities abound in emerging markets where healthcare infrastructure is improving, and awareness about gene therapies is increasing. Companies that can navigate regulatory landscapes and demonstrate long-term efficacy and safety are poised to capture significant market share. With ongoing technological advancements and strategic partnerships, the hemophilia gene therapy market is set to witness sustained growth.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by Functionality
  • 2.8 Key Market Highlights by Installation Type
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Hemophilia A
    • 4.1.2 Hemophilia B
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Gene Therapy Vectors
    • 4.2.2 Recombinant Proteins
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Adeno-Associated Virus (AAV) Vector
    • 4.3.2 Lentivirus Vector
    • 4.3.3 Retrovirus Vector
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Clinical Trials
    • 4.4.2 Research and Development
    • 4.4.3 Commercial Use
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Specialty Clinics
    • 4.5.3 Research Institutes
    • 4.5.4 Biopharmaceutical Companies
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 In Vivo Gene Therapy
    • 4.6.2 Ex Vivo Gene Therapy
  • 4.7 Market Size & Forecast by Functionality (2020-2035)
    • 4.7.1 Gene Addition
    • 4.7.2 Gene Editing
  • 4.8 Market Size & Forecast by Installation Type (2020-2035)
    • 4.8.1 Standalone
    • 4.8.2 Integrated
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Therapeutic Solutions
    • 4.9.2 Diagnostic Solutions

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Process
      • 5.2.1.7 Functionality
      • 5.2.1.8 Installation Type
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Process
      • 5.2.2.7 Functionality
      • 5.2.2.8 Installation Type
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Process
      • 5.2.3.7 Functionality
      • 5.2.3.8 Installation Type
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Process
      • 5.3.1.7 Functionality
      • 5.3.1.8 Installation Type
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Process
      • 5.3.2.7 Functionality
      • 5.3.2.8 Installation Type
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Process
      • 5.3.3.7 Functionality
      • 5.3.3.8 Installation Type
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Process
      • 5.4.1.7 Functionality
      • 5.4.1.8 Installation Type
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Process
      • 5.4.2.7 Functionality
      • 5.4.2.8 Installation Type
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Process
      • 5.4.3.7 Functionality
      • 5.4.3.8 Installation Type
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Process
      • 5.4.4.7 Functionality
      • 5.4.4.8 Installation Type
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Process
      • 5.4.5.7 Functionality
      • 5.4.5.8 Installation Type
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Process
      • 5.4.6.7 Functionality
      • 5.4.6.8 Installation Type
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Process
      • 5.4.7.7 Functionality
      • 5.4.7.8 Installation Type
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Process
      • 5.5.1.7 Functionality
      • 5.5.1.8 Installation Type
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Process
      • 5.5.2.7 Functionality
      • 5.5.2.8 Installation Type
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Process
      • 5.5.3.7 Functionality
      • 5.5.3.8 Installation Type
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Process
      • 5.5.4.7 Functionality
      • 5.5.4.8 Installation Type
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Process
      • 5.5.5.7 Functionality
      • 5.5.5.8 Installation Type
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Process
      • 5.5.6.7 Functionality
      • 5.5.6.8 Installation Type
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Process
      • 5.6.1.7 Functionality
      • 5.6.1.8 Installation Type
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Process
      • 5.6.2.7 Functionality
      • 5.6.2.8 Installation Type
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Process
      • 5.6.3.7 Functionality
      • 5.6.3.8 Installation Type
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Process
      • 5.6.4.7 Functionality
      • 5.6.4.8 Installation Type
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Process
      • 5.6.5.7 Functionality
      • 5.6.5.8 Installation Type
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 uni Qure
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Bio Marin Pharmaceutical
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Sangamo Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Spark Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Freeline Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Hemab Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Dimension Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 REGENXBIO
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Intellia Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Editas Medicine
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 CRISPR Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Thermo Fisher Scientific
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Voyager Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Audentes Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Bluebird Bio
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Precision Bio Sciences
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Poseida Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Generation Bio
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Logic Bio Therapeutics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Beam Therapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us